A phase 3b, randomized, open-label clinical study to demonstrate non-inferiority in virologic response rates of HIV-1 RNA suppression < 400 copies/mL of TDF/FTC/RPV versus TDF/FTC/EFV in first-line antiretroviral NNRTI-based suppressed patients

This randomized study will show that the efficacy of tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) is equivalent to the standard treatment TDF/FTC/efavirenz (TDF/FTC/EFV) in patients with plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) levels less than 400 copies per mL after 48 weeks.